SBM.V · Sirona Biochem Corp

-

Please sign in to comment on SBM.V

1 Comment

Admin

3 years, 7 months ago

Sirona Biochem Corp is currently in a long term downtrend where the price is trading 25.5% below its 200 day moving average.

From a valuation standpoint, the stock is 27.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 740.0.

Sirona Biochem Corp's total revenue rose by inf% to $18K since the same quarter in the previous year.

Its net income has increased by 64.6% to $-676K since the same quarter in the previous year.

Finally, its free cash flow fell by 23.9% to $-745K since the same quarter in the previous year.

Based on the above factors, Sirona Biochem Corp gets an overall score of 3/5.

Industry	Biotechnology
Sector	Healthcare
ISIN	CA82967M1005
CurrencyCode	CAD
Exchange	V

Beta	-0.41
Dividend Yield	0.0%
Target Price	0.73
PE Ratio	None
Market Cap	26M

ABOUT

Sirona Biochem Corp

Sirona Biochem Corp., a cosmetic ingredient and drug discovery company, develops and sells cosmetic and pharmaceutical active ingredients in Canada and France. Its programs include cosmetic skin lightener and diabetes drug; and other projects include the development of an anti-aging/cell protection library, novel anti-wrinkle compound, and anti-viral program. Sirona Biochem Corp. has a research collaboration agreement with the International Centre for Genetic Engineering and Biotechnology (ICGEB) to develop antiviral library of compounds. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. The company was incorporated in 2006 and is headquartered in Vancouver, Canada.

SBM.V · Sirona Biochem Corp

-

Sirona Biochem Corp

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Sirona Biochem Corp using a moving average strategy